The Role of Endothelin in Pulmonary Hypertension

Mass General Brigham

Status and phase: Completed; Phase 2

Conditions: Pulmonary Hypertension

Treatments: Drug: BQ-123

Study type: Interventional

Funder types: Other

Identifiers

NCT00759408

1999-P-003126

Details and patient eligibility

About

The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.

Full description

Endothelin levels are increased in patients with pulmonary hypertension. We wish to compare the effect of an endothelin antagonist on pulmonary hypertension due to a variety of causes.

Enrollment: 38 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers or known diagnosis of pulmonary hypertension

Exclusion criteria

• hypertension due to other reasons (not pulmonary)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

38 participants in 1 patient group

1

Experimental group

Description:

BQ-123

Treatment:

Drug: BQ-123